Registry update — unassessed
Targeting Cellular Senescence With Fisetin for Improving Vascular Endothelial Function in Older Adults
Trial registry update: NOT_YET_RECRUITING. No results reported in the supplied registry record.
RCTRoutine significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Oct 13, 2026 · Discovered: Oct 13, 2026 · Assessed: — · Research update
What it does not prove
- No data are provided on study outcomes or findings, making it impossible to assess whether fisetin affected endothelial function or cellular senescence markers.
- The mechanism linking any effects of fisetin to senescence reduction versus other pathways cannot be determined from this abstract.
- Safety and tolerability outcomes are not reported.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- —
- Population
- Older adults
- Primary outcome
- Vascular endothelial function
- Effect size
- —
- Significance
- Not reported
- Journal
- University of Colorado, Boulder
- Published
- Oct 13, 2026
Sources
Primary source
- University of Colorado, Boulder ↗Clinical trial
Recorded source passages
Abstract or registry material supplied for assessment; source version 1. This is not a claim of full-text review.
This clinical trial will assess if supplementation with the natural compound fisetin can improve vascular endothelial function in older adults
The clinical trial will also assess if any effects of fisetin on endothelial function are associated with reduced cellular senescence
The study will also evaluate safety, tolerability and adherence with fisetin treatment
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.